Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial
Abstract
OBJECTIVES: To assess whether reinforced pneumococcal vaccination strategies improve immunogenicity in patients with ANCA-associated vasculitis (AAV) receiving rituximab. METHODS: PNEUMOVAS was a multicentre, open-label, randomized phase 2 superiority trial. Between February 2018 and May 2020, adults with newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis scheduled for rituximab induction were randomized (1:1:1) to: standard vaccination (Arm A: one PCV13 dose at day 0 followed by PPV23 at month 5), reinforced regimen 1 (Arm B: two PCV13 doses at day 0 and two at day 7 followed by PPV23), or reinforced regimen 2 (Arm C: four PCV13 doses at day 0 followed by PPV23). The primary endpoint was the breadth of the ELISA antibody response at month 6, categorized as a response to 0-3, 4-6, 7-9, or 10-12 of 12 shared serotypes, and analyzed with an age-adjusted proportional odds model in the modified intention-to-treat population. RESULTS: Of 120 planned patients, 96 were randomized (30, 32, and 34 in Arms A, B, and C) and 95 were analyzed (median age 62 years; 47/95 [49.5%] male; median follow-up 17.9 months). At month 6, 1/30 (3.3%), 5/32 (15.6%), and 2/33 (6.1%) participants in Arms A, B, and C responded to 7-9 serotypes, and none to 10-12. Compared with the standard regimen, Arm B significantly improved the breadth of the response (proportional OR 4.14, 97.5% CI 1.08 to 15.88; p=0.018), whereas Arm C showed a non-significant trend (pOR 3.08, 97.5% CI 0.80 to 11.92). Reinforced schedules also improved opsonophagocytic activity for several serotypes. Vaccine responses declined over time in all groups. Vaccination was overall well tolerated, with no vaccine-related serious adverse events. CONCLUSIONS: In AAV patients receiving rituximab, reinforced pneumococcal vaccination strategies improved humoral immunogenicity compared with the standard regimen (ClinicalTrials.gov Identifier: NCT03069703).
Related
- Pneumococcal nasopharyngeal carriage, serotype distribution, and vaccination status in hospitalized children in Latvia: A cross-sectional study during the post-PCV13, pre-PCV15/PCV20 transition period
- Effectiveness of pneumococcal vaccination campaigns in humanitarian settings: A modelling study
- Authors’ Reply: Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange
- CD8+ stem cell-like memory T cells: Unveiling the potential for next-generation vaccination strategies
- Leaky protection reveals three patterns in the relative advantages of vaccination strategies across transmission intensity
BibTeX
@article{terrier2026reinforced,
title = {{Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial}},
author = {Benjamin Terrier and Laura Richert and Grégory Pugnet and Olivier Aumaître and Olivier Moranne and Noémie Huchet and Lucie Chevrier and Elisabeth Diot and Alexandre Karras and Fabrice Bonnet and Claire de Moreuil and Eric Hachulla and Thomas Le Gallou and Céline Lebas and Julien Campagne and Cédric Rafat and Maxime Samson and Jean-François Augusto and Grégoire Couvrat-Devergne and Cécile Janssen and Thierry Martin and Thomas Quemeneur and Pierre-Louis Carron and Cécile-Audrey Durel and Khalil El Karoui and Aurélie Grados and Mathieu Puyade and Marc Ruivard and Yurdagul Uzunhan and Jean-François Viallard and Xavier Puéchal and Loïc Guillevin and Corine Desaint and Hendy Abdoul and Carine Bellera and Frédéric Batteux and Odile Launay},
journal = {Clinical Microbiology and Infection},
year = {2026},
month = nov,
doi = {10.1016/j.cmi.2026.11.004},
url = {https://hal.science/hal-05864943v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial
AU - Benjamin Terrier
AU - Laura Richert
AU - Grégory Pugnet
AU - Olivier Aumaître
AU - Olivier Moranne
AU - Noémie Huchet
AU - Lucie Chevrier
AU - Elisabeth Diot
AU - Alexandre Karras
AU - Fabrice Bonnet
AU - Claire de Moreuil
AU - Eric Hachulla
AU - Thomas Le Gallou
AU - Céline Lebas
AU - Julien Campagne
AU - Cédric Rafat
AU - Maxime Samson
AU - Jean-François Augusto
AU - Grégoire Couvrat-Devergne
AU - Cécile Janssen
AU - Thierry Martin
AU - Thomas Quemeneur
AU - Pierre-Louis Carron
AU - Cécile-Audrey Durel
AU - Khalil El Karoui
AU - Aurélie Grados
AU - Mathieu Puyade
AU - Marc Ruivard
AU - Yurdagul Uzunhan
AU - Jean-François Viallard
AU - Xavier Puéchal
AU - Loïc Guillevin
AU - Corine Desaint
AU - Hendy Abdoul
AU - Carine Bellera
AU - Frédéric Batteux
AU - Odile Launay
PY - 2026
DA - 2026/11/15
JO - Clinical Microbiology and Infection
DO - 10.1016/j.cmi.2026.11.004
UR - https://hal.science/hal-05864943v1
AB - OBJECTIVES: To assess whether reinforced pneumococcal vaccination strategies improve immunogenicity in patients with ANCA-associated vasculitis (AAV) receiving rituximab. METHODS: PNEUMOVAS was a multicentre, open-label, randomized phase 2 superiority trial. Between February 2018 and May 2020, adults with newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis scheduled for rituximab induction were randomized (1:1:1) to: standard vaccination (Arm A: one PCV13 dose at day 0 followed by PPV23 at month 5), reinforced regimen 1 (Arm B: two PCV13 doses at day 0 and two at day 7 followed by PPV23), or reinforced regimen 2 (Arm C: four PCV13 doses at day 0 followed by PPV23). The primary endpoint was the breadth of the ELISA antibody response at month 6, categorized as a response to 0-3, 4-6, 7-9, or 10-12 of 12 shared serotypes, and analyzed with an age-adjusted proportional odds model in the modified intention-to-treat population. RESULTS: Of 120 planned patients, 96 were randomized (30, 32, and 34 in Arms A, B, and C) and 95 were analyzed (median age 62 years; 47/95 [49.5%] male; median follow-up 17.9 months). At month 6, 1/30 (3.3%), 5/32 (15.6%), and 2/33 (6.1%) participants in Arms A, B, and C responded to 7-9 serotypes, and none to 10-12. Compared with the standard regimen, Arm B significantly improved the breadth of the response (proportional OR 4.14, 97.5% CI 1.08 to 15.88; p=0.018), whereas Arm C showed a non-significant trend (pOR 3.08, 97.5% CI 0.80 to 11.92). Reinforced schedules also improved opsonophagocytic activity for several serotypes. Vaccine responses declined over time in all groups. Vaccination was overall well tolerated, with no vaccine-related serious adverse events. CONCLUSIONS: In AAV patients receiving rituximab, reinforced pneumococcal vaccination strategies improved humoral immunogenicity compared with the standard regimen (ClinicalTrials.gov Identifier: NCT03069703).
SN - 1198-743X
SN - 1469-0691
ER -